188
Participants
Start Date
May 19, 2022
Primary Completion Date
December 6, 2024
Study Completion Date
December 6, 2024
TNM Device
Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive tvCVS device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
Mount Sinai Hospital, New York
Thomas Jefferson University, Philadelphia
University of Pennsylvania, Philadelphia
Georgetown University, McLean
Riverside Neurology Specialists, Newport News
Meridian Clinical Research, Raleigh
Medical University of South Carolina, Charleston
Headlands Research Orlando, Orlando
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
USF Parkinson's Disease and Movement Disorders Center, Tampa
Veracity Neuroscience, Memphis
Cleveland Clinic, Cleveland
Quest Research, Farmington Hills
Mercy Health Saint Mary's, Grand Rapids
University of Kansas Medical Center - Parkinson's Disease Center, Kansas City
Houston Methodist Neurological Institute, Houston
Texas Movement Disorder Specialist, Georgetown
CenExel Rocky Mountain Clinical Research, Englewood
Movement Disorder Center of Arizona, Scottsdale
University of New Mexico, Albuquerque
Cedars-Sinai Medical Center, Los Angeles
Inland Northwest Research, Spokane
King's College Hospital NHS Foundation Trust, London
Lead Sponsor
Scion NeuroStim
INDUSTRY